Skip to menu Skip to content Skip to footer
News

Second antibiotic no advantage for treating super-bug Golden Staph

13 February 2020
Decorative

A world-first clinical trial has called into question the effectiveness of using more than one antibiotic to treat the deadly ‘super-bug’, Methicillin-resistant staphylococcus aureus (MRSA) Bacteremia, commonly known as Golden Staph.

Researchers from The University of Queensland, in collaboration with global counterparts, have found using two antibiotics to treat MRSA infection provides no advantage over using a single antibiotic.

The three-year multi-centre study involved 352 patients at 27 hospitals in Australia, Singapore, Israel and New Zealand.

UQ Professor David Paterson said researchers tested whether adding a second antibiotic for seven days to a standard antibiotic treatment would lead to improved health outcomes after 90 days.

“We found no significant difference in mortality, bacteria in the blood, infection relapse or treatment failure,” Professor Paterson said.

“Furthermore, patients who received two antibiotics had a higher rate of side effects related to kidney function than those who received just one antibiotic. 

“For many years doctors have debated whether MRSA should be treated with two antibiotics or just one antibiotic.

“This trial now puts that debate to rest and will have a huge impact on how antibiotics are used for MRSA infections worldwide.

“These findings are hugely important on a number of levels – one of the most important implications of the research is how it can impact antibiotic use and the global issue of antibiotic resistance.”

MRSA is a common and very serious cause of infection that affects more than 10,000 people in Australia every year, especially women aged 60 and over.

Treating the infection can take up to several months and requires lab testing for diagnosis.

This study has been published in the journal JAMA.

Collaborating partners included the University of Melbourne, Menzies School of Health Research, UQ, Brisbane’s Royal Brisbane and Women’s Hospital and Princess Alexandra Hospital,  Cairns Hospital, Austin Health,  Concord Repatriation General Hospital, Blacktown Hospital, Royal Prince Alfred Hospital, NSW Health, Duke University, Eastern Health, Flinders Medical Centre, Footscray Hospital, , The Queen Elizabeth Hospital, Narin BAK, The Royal Adelaide Hospital, Westmead Hospital, Sydney and Wollongong Public Hospital.

Related articles

More than 2700 people are living with ALS in Australia and currently there is no cure or effective treatment

Clinical trial to repurpose heart medication for MND treatment

UQ researchers are investigating whether a common heart medication can also be used to treat people living with the most common form of motor neurone disease (MND).
1 September 2025
A illustration of a human with the words "bias" written where the brain would be

Change my mind: study finds it’s possible to teach students good decision-making

Unconscious biases can cloud rational decision-making, but a UQ study has found erroneous thinking can be reversed with training.
27 August 2025

Media contact

Subscribe to UQ News

Get the latest from our newsroom.